Congratulations to Jon and the team.
3 for 3 with the P2 trials with powerful, significant gains across the board.
Outstanding and a credit to their meticulous planning and vision for our pipeline.
Clean air now to the P3 discussions with the FDA, but I would expect BP to put their cards on the table in the very near term now.
And they’ll need a very compelling hand…
Ann: Phase 2 trial shows significant improvements in Angelman, page-55
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.280(2.28%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.52 | $12.73 | $12.26 | $8.152M | 652.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 665 | $12.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.55 | 235 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |